With 0.64 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.98 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $15.6 whereas the lowest price it dropped to was $14.15. The 52-week range on RGC shows that it touched its highest point at $83.60 and its lowest point at $0.08 during that stretch. Beta for the stock currently stands at 2.24.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RGC was down-trending over the past week, with a drop of -1.69%, but this was down by -81.41% over a month. Three-month performance surged to 1922.02% while six-month performance rose 11284.30%. The stock gained 11053.85% in the past year, while it has gained 16347.76% so far this year.
Float and Shares Shorts:
At present, 494.49 million RGC shares are outstanding with a float of 19.01 million shares on hand for trading. On 2025-06-13, short shares totaled 1.05 million, which was 21.0 higher than short shares on 1747267200. In addition to Mr. Yat-Gai Au as the firm’s Founder, Chairman & CEO, Ms. Michelle Chan serves as its Financial Controller & Principal Financial Officer.
Institutional Ownership:
Through their ownership of 0.00068000006 of RGC’s outstanding shares, institutional investors have minority control over the company.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
